Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDIOPROTECT Trial
NCT07654426Phase 2Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexrazoxane in Cardiotoxicity (6 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Left Ventricular Ejection Fraction. Started Aug 2026; status: recruiting.
02
Drugs
dexrazoxane
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07654426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654426.